245 related articles for article (PubMed ID: 24125101)
61. Effect of CYP2D6 polymorphisms on breast cancer recurrence.
Morrow PK; Serna R; Broglio K; Pusztai L; Nikoloff DM; Hillman GR; Fontecha M; Li R; Michaud L; Hortobagyi G; Gonzalez-Angulo AM
Cancer; 2012 Mar; 118(5):1221-7. PubMed ID: 21823108
[TBL] [Abstract][Full Text] [Related]
62. Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
Pharmacogenomics; 2017 Jun; 18(8):755-756. PubMed ID: 28593824
[TBL] [Abstract][Full Text] [Related]
63. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
[TBL] [Abstract][Full Text] [Related]
64. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.
Mayer SE; Weiss NS; Chubak J; Doody DR; Carlson CS; Makar KW; Wurscher MA; Malone KE
Cancer Causes Control; 2019 Jan; 30(1):103-112. PubMed ID: 30542984
[TBL] [Abstract][Full Text] [Related]
65. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
66. Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.
Argalácsová S; Slanař O; Vítek P; Tesařová P; Bakhouche H; DraŽďáková M; Bartošová O; Zima T; PertuŽelka L
Physiol Res; 2015; 64(Suppl 4):S539-47. PubMed ID: 26681084
[TBL] [Abstract][Full Text] [Related]
67. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Sim S; Lövrot J; Lindh JD; Bergh J; Xie H
Pharmacogenomics; 2018 Aug; 19(13):1027-1037. PubMed ID: 30022682
[TBL] [Abstract][Full Text] [Related]
68. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
Teh LK; Mohamed NI; Salleh MZ; Rohaizak M; Shahrun NS; Saladina JJ; Shia JK; Roslan H; Sood S; Rajoo TS; Muniandy SP; Henry G; Ngow HA; Hla U KT; Din J
AAPS J; 2012 Mar; 14(1):52-9. PubMed ID: 22183189
[TBL] [Abstract][Full Text] [Related]
69. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.
Toyama T; Yamashita H; Sugiura H; Kondo N; Iwase H; Fujii Y
Jpn J Clin Oncol; 2009 Oct; 39(10):651-6. PubMed ID: 19596663
[TBL] [Abstract][Full Text] [Related]
70. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
Johnson JA; Hamadeh IS; Langaee TY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638249
[No Abstract] [Full Text] [Related]
71. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
[TBL] [Abstract][Full Text] [Related]
72. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Brooks JD; Comen EA; Reiner AS; Orlow I; Leong SF; Liang X; Mellemkjær L; Knight JA; Lynch CF; John EM; Bernstein L; Woods M; Doody DR; ; Malone KE; Bernstein JL
Breast Cancer Res; 2018 Dec; 20(1):149. PubMed ID: 30526633
[TBL] [Abstract][Full Text] [Related]
73. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO; van Schaik RH; Vletter-Bogaartz JM; van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; van de Velde CJ; Nortier JW; Gelderblom H; Guchelaar HJ
Breast Cancer Res Treat; 2013 Jul; 140(2):363-73. PubMed ID: 23842856
[TBL] [Abstract][Full Text] [Related]
74. Association between CYP2D6 polymorphisms and breast cancer outcomes.
Dieudonné AS; Van Belle V; Neven P
JAMA; 2010 Feb; 303(6):516-7; author reply 517. PubMed ID: 20145225
[No Abstract] [Full Text] [Related]
75. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
Thorén L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Breast Cancer Res Treat; 2021 Dec; 190(3):451-462. PubMed ID: 34570302
[TBL] [Abstract][Full Text] [Related]
76. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Goetz MP; Sun JX; Suman VJ; Silva GO; Perou CM; Nakamura Y; Cox NJ; Stephens PJ; Miller VA; Ross JS; Chen D; Safgren SL; Kuffel MJ; Ames MM; Kalari KR; Gomez HL; Gonzalez-Angulo AM; Burgues O; Brauch HB; Ingle JN; Ratain MJ; Yelensky R
J Natl Cancer Inst; 2014 Dec; 107(2):. PubMed ID: 25490892
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
[TBL] [Abstract][Full Text] [Related]
78. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
[TBL] [Abstract][Full Text] [Related]
79. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
80. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Xu Y; Sun Y; Yao L; Shi L; Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; He L; Li P; Xie Y
Ann Oncol; 2008 Aug; 19(8):1423-1429. PubMed ID: 18407954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
